Issues

Role of maternal immune activation in neurodevelopment disorders and possible pharmacological treatment

F. Aria, A. Mastinu, G. Maccarinelli, M. Premoli, M. Memo, S. A. Bonini

Vol. 2 (No.1) 2020 April
Post-it In Pharmacology,
doi: 10.36118/pharmadvances.01.2020.15

Aberrant immune activity during vulnerable and critical periods of neurodevelopment could participate in the generation of neurological dysfunction characteristic of several neurodevelopmental disorders (NDDs), including autism spectrum disorders and schizophrenia. Numerous epidemiological studies have shown a link between maternal infections and NDDs risk; animal models of Maternal Immune Activation (MIA) have confirmed this association. No current therapy exists for treatment or prevention of ASD. Drugs currently used for ASD are mainly symptomatic lacking specificity and are often ineffective for behavioural deficits. In order to find new drug therapy that acts on causes of ASD not on symptoms, a nonsteroidal anti-inflammatory drug, was used.

Full text PDF

Table of Content: Vol. 2 (No.1) 2020 April

  1. Official Statement of the section of Clinical Pharmacology of the Italian Society of Pharmacology on the use of ACE- inhibitors or angiotensin receptor blockers in COVID-19 infection with commentary

    G. Trifirò 1,2, L. Berrino 3, M. Del Re 4, R. Bernardini 5, C. Chiamulera 6, A. D’Avolio 7, F. Scaglione 8, A. Capuano 9, E. Clementi 10, R. Danesi 4, L. Pani 11, A. Catapano 12, G. Racagni 12, on behalf of the Section of Clinical Pharmacology of Italian Society of Pharmacology
    Letter to the Editor, 1-5
    doi: 10.36118/pharmadvances.01.2020.01
    Full text PDF

  2. Official Statement of the section of Clinical Pharmacology of Italian Society of Pharmacology on Non-steroidal anti-inflammatory drugs (NSAIDs) and the increased risk of complications during infections with commentary

    A. Capuano 1, F. Scaglione 2, L. Berrino 3, M. Del Re 4, R. Bernardini 5, C. Chiamulera 6, A. D’Avolio 7, G. Trifirò 8,9, E. Clementi 10, R. Danesi 4, L. Pani 11, G. Racagni 12 on behalf of the section of Clinical Pharmacology of Italian Society of Pharmacology
    Letter to the Editor, 6-10
    doi: 10.36118/pharmadvances.01.2020.03
    Full text PDF

  3. Angiotensin-converting enzyme-2 (ACE2): New opportunity or red herring?

    M. Vicenzi 1,2, A. Corsini 3,4, M. Ruscica 3
    Short Article, 11-13
    doi: 10.36118/pharmadvances.01.2020.05
    Full text PDF

  4. The contribution of the clinical laboratory to the new medicine paradigm

    L. Mariani, D. Pedrazzini
    Research Article, 14-18
    doi: 10.36118/pharmadvances.01.2020.06
    Full text PDF

  5. Independent Research in Italy

    G. Corbellini
    Opinion Paper, 19-30
    doi: 10.36118/pharmadvances.01.2020.07
    Full text PDF

  6. Treatment of chronic pain in Italy: therapeutic appropriacy of opioids and fear of addiction. The situation in Italy vs. USA

    D. Fornasari 1, G. Gerra 2, S. Maione 3, G. Mannaioni 4, A. Mugelli 5, D. Parolaro 6, P. Romualdi 7, P. Sacerdote 8
    Research Article, 31-40
    doi: 10.36118/pharmadvances.01.2020.08
    Full text PDF

  7. Herb and spice mediated interactions in oncologic patients treated with chemotherapy

    F. Turco, A. Elio Sprio, I. Bertaggia, T. Armando, S. Storto, S. Allegra, S. De Francia, M. V. Mussa
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.10
    Full text PDF

  8. Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy

    N. Lombardi, G. Crescioli, A. Bettiol, M. Tuccori, M Rossi, R. Bonaiuti, C. Ravaldi, M. Levi, A. Mugelli, S. Ricci, F. Lippi, C. Azzari, P. Bonanni, A. Vannacci
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.11
    Full text PDF

  9. Factors influencing the antiplatelet therapy in patients requiring vascular surgery

    C. Sellitto, V. Conti Valeria, V. Manzo Valentina, T. Iannaccone, M. Costantino, M. Torsiello, G. Di Fiore, G. Accarino, G. Nicolella, G. Corbi, A. Filippelli
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.12
    Full text PDF

  10. Effect of Lactobacillus farciminis supplementation in preventing LPS-induced hippocampal neuroinflammation, in mice

    C. Petrella, G. Strimpakos, F. De Santa, M. Fiore, D. Mora, S. Arioli, S. Farioli-Vecchioli
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.13
    Full text PDF

  11. Role of maternal immune activation in neurodevelopment disorders and possible pharmacological treatment

    F. Aria, A. Mastinu, G. Maccarinelli, M. Premoli, M. Memo, S. A. Bonini
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.15
    Full text PDF

  12. The novel fentanyl-analog “Acrylofentanyl” impairs motor, sensorimotor and cardiovascular functions in mice.

    S. Bilel, R. Arfè, M. Tirri, C. Trapella, P. Frisoni, M. Neri, M. Marti
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.14
    Full text PDF

  13. A new HPLC-UV method compared with HPLC-MS for daptomycin levels in human plasma samples

    G. Luci, F. Cucchiara, M. Lastella, L. Ciofi, R. Danesi, A. Di Paolo
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.16
    Full text PDF

  14. Ultrasonic communication deficits in p50 KO mice and effect of maternal enrichment

    M. Premoli, S. A. Bonini, A. Mastinu, G. Maccarinelli, G. Paiardi, F. Aria, M. Memo
    Post-it In Pharmacology,
    doi: 10.36118/pharmadvances.01.2020.17
    Full text PDF
©2024 Edra S.p.A. - P.Iva 08056040960